A comparison of IROC and ACDS on-site audits of reference and non-reference dosimetry

Jessica Lye
Australian Clinical Dosimetry Service, ARPANSA, Melbourne, Australia

Stephen Kry
Imaging and Radiation Oncology Core Houston QA Center, MD Anderson Cancer Center, Houston, TX, USA

Maddison Shaw
Australian Clinical Dosimetry Service, ARPANSA, Melbourne, Australia

Francis Gibbons
Australian Clinical Dosimetry Service, ARPANSA, Melbourne, Australia
Sunshine Coast Hospital and Health Service, Birtinya, Qld, Australia

Stephanie Keehan
Australian Clinical Dosimetry Service, ARPANSA, Melbourne, Australia

Joerg Lehmann
Australian Clinical Dosimetry Service, ARPANSA, Melbourne, Australia
Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia

Tomas Kron
Peter MacCallum Cancer Centre, Melbourne, Australia

David Followill
Imaging and Radiation Oncology Core Houston QA Center, MD Anderson Cancer Center, Houston, TX, USA

Ivan Williams
Australian Clinical Dosimetry Service, ARPANSA, Melbourne, Australia

(Received 9 May 2019; revised 19 July 2019; accepted for publication 5 August 2019; published 25 October 2019)

Purpose: Consistency between different international quality assurance groups is important in the progress toward similar standards and expectations in radiotherapy dosimetry around the world, and in the context of consistent clinical trial data from international trial participants. This study compares the dosimetry audit methodology and results of two international quality assurance groups performing a side-by-side comparison at the same radiotherapy department, and interrogates the ability of the audits to detect deliberately introduced errors.

Methods: A comparison of the core dosimetry components of reference and non-reference audits was conducted by the Imaging and Radiation Oncology Core (IROC, Houston, USA) and the Australian Clinical Dosimetry Service (ACDS, Melbourne, Australia). A set of measurements were conducted over 2 days at an Australian radiation therapy facility in Melbourne. Each group evaluated the reference dosimetry, output factors, small field output factors, percentage depth dose (PDD), wedge, and off-axis factors according to their standard protocols. IROC additionally investigated the Electron PDD and the ACDS investigated the effect of heterogeneities. In order to evaluate and compare the performance of these audits under suboptimal conditions, artificial errors in PDD, EDW, and small field output factors were introduced into the 6 MV beam model to simulate potential commissioning/modeling errors and both audits were tested for their sensitivity in detecting these errors.

Results: With the plans from the clinical beam model, almost all results were within tolerance and at an optimal pass level. Good consistency was found between the two audits as almost all findings were consistent between them. Only two results were different between the results of IROC and the ACDS. The measurements of reference FFF photons showed a discrepancy of 0.7% between ACDS and IROC due to the inclusion of a 0.5% nonuniformity correction by the ACDS. The second difference between IROC and the ACDS was seen with the lung phantom. The asymmetric field behind lung measured by the ACDS was slightly (0.3%) above the ACDS’s pass (optimal) level of 3.3%. IROC did not detect this issue because their measurements were all assessed in a homogeneous phantom. When errors were deliberately introduced neither audit was sensitive enough to pick up a 2% change to the small field output factors. The introduced PDD change was flagged by both audits. Similarly, the introduced error of using 25° wedge instead of 30° wedge was detectible in both audits as out of tolerance.
Conclusions: Despite different equipment, approach, and scope of measurements in on-site audits, there were clear similarities between the results from the two groups. This finding is encouraging in the context of a global harmonized approach to radiotherapy quality assurance and dosimetry audit. © 2019 The Authors. Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine. [https://doi.org/10.1002/mp.13800]

Key words: Australian Clinical Dosimetry Service, dosimetry audit, Imaging and Radiation Oncology Core, international comparison, quality assurance, Radiation Therapy audit

1. INTRODUCTION

Independent audits of dosimetry in radiotherapy clinics are an excellent quality improvement tool for detecting systemic errors in dosimetry and encouraging consistency in radiotherapy practice. Dosimetry audits are recognized as international best practice for departmental quality assurance and clinical trial accreditation and have uncovered systemic problems with radiotherapy dose determination, such as dosimetric inaccuracies in heterogeneous dose calculations and small field dose calculations, as well as identifying unique errors in calibration and dose determination at individual clinics.

Dosimetry audits can test different elements of the radiotherapy chain, including a simple check of reference dosimetry (Level I audit), increasing in complexity to an end-to-end dose delivery evaluation (Level III). An intermediate (Level II) audit is one that probes the commissioning data and development of the treatment planning system (TPS) beam model. Such a clinical dosimetry audit can take many forms, as any type of dosimetric measurement that falls between reference dosimetry and full end-to-end scanning, planning, and delivery style audits could be classified as a Level II audit. Ideally, for a given level of audit, the audit should be sensitive to the detection of dosimetric deficiencies regardless of the means by which it is conducted. This means, implicitly, that audits performed by different groups worldwide should, despite differences in methodology, be consistent in their findings. Indeed, consistency between different international QA groups is a key focus and concern of such groups as the Global Harmonisation Group (GHG; www.rtqaharmonization.com).

The ability of different audit methodologies to produce comparable results is not given in assessing radiotherapy performance. Indeed, many recent studies have shown inconsistent (and inaccurate) performance of common quality assurance (QA) tools, particularly in the assessment of IMRT.

Therefore, a comparison of the core components of on-site Level I and II audits was conducted by the Imaging and Radiation Oncology Core Houston QA Center (IROC, Houston, USA) and the Australian Clinical Dosimetry Service (ACDS, Melbourne, Australia). This study evaluated if the different dosimetric approach from two groups on opposite sides of the world, and using separate primary dosimetry standards and calibration protocols, could comparably assess radiotherapy quality and identify errors deliberately introduced in the planning system. This was done through a head-to-head set of measurements conducted at an Australian radiation therapy facility in Melbourne.

2. MATERIALS AND METHODS

2.A. Audit components

The dosimetric components of IROC and ACDS on-site audits of photon beams include an evaluation of: beam output, output factors (including for small fields), depth dose data (for different field sizes), off-axis factors, and wedge factors. Electron output is also evaluated. The specific components for each group are shown in Table I. From this table, it is clear that many similar components of clinical dosimetry are tested, but that these are done with different implementations, equipment, and methodologies.

Both the IROC and the ACDS include additional components in their on-site audit. For example, IROC performs a picket fence test of the MLC, mechanical checks on the linac, and a Winston–Lutz test for IGRT. The ACDS performs test cases from TG-119 and MLC commissioning tests including the “Chair” test and the FOURL. While these tests are important components of an independent audit, this work focuses on core conformal dosimetry components and analysis listed in Table I.

Dosimetric audits cover multiple modalities of radiation therapy dose delivery and the approach to covering modalities differs between auditing groups. The IROC on-site audit covers a number of modalities in a single visit. The ACDS Level Ib audits cover reference beams and the ACDS Level II audit covers non-reference conformal photons, IMRT, and VMAT. This work compares the ACDS Level Ib and Level II audits to match the modalities covered by the IROC on-site audit.

2.B. Audit materials and methods

The IROC determines the absorbed dose to water per monitor unit, for megavoltage photon and electron beams, under the Radiation Oncology facility’s reference conditions following the AAPM TG-51 protocol. IROC brings all their own equipment on-site including their own custom one-dimensional scanning water tank [Fig. 1(a)]. Farmer type ionization chambers (primarily the Exradin A12, Standard Imaging Middleton, WI) are used for reference photon, electron, and FFF dose measurements. Charge is measured with a Standard Imaging model MAX 4000 electrometer. All ion chambers and electrometers are calibrated every second year and checked before each site visit by an Accredited Dosimetry Calibration Laboratory.

Non-reference dose assessments are conducted by IROC based on point dose measurements in the same water phantom [Fig. 1(b)]. The institution, using their TPS, calculates
the dose in a virtual water phantom to the points and conditions prescribed by IROC (Table I). Measurements are then conducted primarily with the same reference A12 Farmer-type ion chamber. However, for the measurement of small field output factors, the Exradin Micropoint A16 ion chamber (Standard Imaging Middleton, WI) is used as the detector.

The ACDS determines absorbed dose to water per monitor unit, for megavoltage photon and electron beams, under the Radiation Oncology facility’s reference conditions following the IAEA TRS-398 Code of Practice. Measurements are conducted in the facility’s water tank [Fig. 1(a)]. All other equipment is brought on-site by the ACDS. Farmer type ionization chambers such as the PTW model TW30013 (PTW Freiburg, Germany) are used for reference photon and FFF dose measurements, and the PTW model 34001 Roos ionization chambers is used for reference electron dose measurements. A nonuniformity correction is applied for FFF measurements to account for the change in profile over the length of a farmer chamber (0.3% and 0.5% for 6FFF and 10FFF, respectively). Charge is measured with a PTW UNIDOS webline reference class electrometer. The ACDS uses ion chamber calibration factors traceable to the Australian Primary Standard of absorbed dose and determined in high-energy beams of similar quality (referred to as “Directly measured”), as recommended by the TRS-398 code. The Farmer type chambers are secondary standards, directly calibrated in comparison with the Australian primary standard. The Roos chamber and the electrometers are also calibrated by the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA).

Non-reference dose assessments were conducted by the ACDS over selected points and planes within a “slab” geometry phantom [Fig. 1(c)]. A CT of the slab phantom is supplied to the Facility for treatment planning based on the multiple cases prescribed by the ACDS (Table I). Dosimetry measurements are made in a custom phantom of CIRS solid water (CIRS Inc, Norfolk, VA, USA), using a PTW Octavius 1500 two-dimensional (2D) ionization chamber array (PTW Freiburg, Germany) as a primary detector and supporting measurements with IBA model CC13 ionization chambers (IBA Dosimetry GmbH, Schwarzenbruck, Germany). The 2D array is calibrated against a Farmer type ionization chamber, which is traceable to the Australian primary standard of absorbed dose. The PTW 60019 microDiamond was used as the primary detector during the measurement of the small field output factors, although at the time of print, the ACDS small field modality was in field trial status and no acceptance or out of tolerance outcome was defined.

The uncertainty in the absolute and relative dose measurements is similar for all of the ion chamber-based large field measurements in this study. The relative standard uncertainty

| Tested dosimetric component of beam model | IROC case | ACDS case |
|------------------------------------------|-----------|-----------|
| Output factors                           | 6 × 6     | 3 × 3     |
|                                          | 15 × 15   | 20 × 20   |
|                                          | 20 × 20   |           |
|                                          | 30 × 30   |           |
| Small field output factors               | 6 × 6     | 3 × 3     |
|                                          | 4 × 4     | 2 × 2     |
|                                          | 3 × 3     | 1 × 1     |
|                                          | 2 × 2     |           |
| PDD                                      | 6 × 6     | 10 × 10   |
|                                          | 20 × 20   | 12 × 12   |
|                                          | 12 × 12   | 12 × 12   |
|                                          | 10 cm     | 5 cm      |
|                                          | 5 cm      |           |
|                                          | 10 cm     |           |
|                                          | 15 cm     | 10 cm     |
|                                          | 15 cm     | 15 cm     |
|                                          | 20 cm     | 20 cm     |
| Wedge (physical and enhanced dynamic)    | 60° EDW 10 × 10 | 60° EDW 10 × 6 |
|                                          | 45° EDW 10 × 10 | 30° EDW 12 × 12 |
|                                          | 45° EDW 15 × 15 |           |
|                                          | 60° Physical 10 × 10 |           |
|                                          | 45° Physical 10 × 10 |           |
| Off-axis factors                         | 5 cm left | All fields (2D array measurements) |
|                                          | 10 cm left/right |           |
|                                          | 10 cm toward/away |           |
|                                          | 15 cm left |           |
| Asymmetric fields                        | N/A       | Asymmetric 10 × 6 |
| Lung                                     | N/A       | 12 × 12   |
|                                          |           | 30° EDW 12 × 12 |
|                                          |           | 60° EDW 10 × 6 |
| Electrons PDD                            | 50% depth dose | N/A       |
|                                          | 80% depth dose |           |
in the dosimetry measurements is estimated to be 1.5% from the TRS-398 calculated uncertainty for high-energy photon beams.

2.C. Audit comparison

The two groups performed their on-site audits, each following their own standard procedures, on the same day in a clinical radiotherapy facility in Melbourne, Australia. The measurements were conducted on a Varian TrueBeam Linear Accelerator (Varian Medical Systems, Palo Alto, CA, USA), commissioned for use with the Eclipse Treatment Planning System v13.6.30 (Varian Medical Systems, Palo Alto, CA, USA). The 6 MV photon beam was fully audited, while (due to time limitations) the 10 FFF and 18 MV beams were only evaluated in terms of beam calibration. Electron beams with energies of 6, 9, 12, 15, and 18 MeV were also evaluated.

In order to evaluate and compare the performance of these audits when radiotherapy deficiencies are present, known errors in percentage depth dose (PDD), EDW, and small field output factors were introduced into the 6 MV beam model to simulate potential commissioning/modeling errors. To simulate an error in 6 MV beam model PDD, the TPR20/10 ratios were increased by 3%. To simulate an error in the EDW commissioning, the plans with a 30° EDW were replaced with a 25° EDW. Finally, the output factors were increased for the 3, 2, and 1 cm² field sizes by 2.4%, 2.1%, and 2.0%, respectively. The slight differences in size of the error were due to rounding differences. The audit plans were recalculated with the erroneous beam models and compared to the original measurements. Both audits were tested for their sensitivity in detecting these errors. The errors were chosen so as to cover a range of beam model components, and also to cover a range of error magnitude. The output factors were increased by the smallest amount, of approximately 2%. As discussed below, 2% is the smallest tolerance used by the two audit groups in assessing the beam modeling. The PDD was adjusted by a slightly larger amount of 3%, a tolerance used by both groups in assessing beam modeling. Finally, an obvious beam model error of using the wrong wedge profile in commissioning was investigated. The audit teams did not know what the introduced errors were prior to performing the audits.

2.D. Audit tolerances and uncertainties

The measurement uncertainties in this report are evaluated using the addendum to TG-51.24 The reference dosimetry measurements for both groups are performed with a reference class farmer chamber with an expanded uncertainty of 1.8% (2\(r\)). Also measured are relative quantities such as output factors, wedge factors, and PDD factors. Taking into account the correlation between uncertainty components relating to the chamber calibration factor and some correction factors, the uncertainty in relative dose measurement using a farmer chamber is estimated to be 0.8% (2\(r\)). The ACDS measures the relative doses with an ionization chamber array. Increased uncertainty is included in the charge history, chamber stability, and irradiation history for assessment of uncertainty in the array-based relative dose measurement, resulting in expanded uncertainty of 1.6% (2\(r\)). Note that all of these uncertainties are assessing uncertainty in the audit group measurement only and does not include uncertainty in facility measurement or TPS calculation.

The IROC and the ACDS have different criteria for defining if an audit result is acceptable, or within tolerance. For reference dose measurements, IROC employs a ±3% tolerance criterion, that is, the ratio of IROC measured to institution stated dose output must be within 3%. All other dose measurements are evaluated as relative factors, that is, output factors, wedge factors, and PDD factors. Given the correlated uncertainties in the measurement and the reduction in uncertainty budget for relative measurements, IROC employs a ±2% tolerance criterion on the ratio of IROC measured to institution calculated relative factors. Results outside these tolerances are presented to the institution as actionable deficiencies with associated recommendations. For each field size measured by the IROC on a particular machine, the product of the IROC/institution ratios for the relative dose factors are also evaluating by selecting first the minimum ratios and then the maximum ratios which could potentially be combined in calculating tumor dose. The products of these
ratios give the range of potential disagreement between IROC and institution on the calculation of stated tumor dose for cooperative trials and should be within ±5.0%.

The ACDS employs an out of tolerance criteria of ±2.1% for reference dose measurements of the reference beam calibration. For reference dosimetry comparisons, there is no treatment planning and ACDS measured dose is compared to the facility measured dose. For non-reference measurements, the ACDS compares the TPS predicted dose to absolute dose measurements. For direct comparison to the TPS predicted dose, the ACDS employs an out of tolerance criterion of ±5.0%. The ACDS simply looks at all points measured in the field, and scores on whether the dose, uncorrected for output of the day, is within the tolerance limit. The philosophy is to measure the dose that would be delivered to a patient. A drawback of this approach is that multiple errors occurring in positive and negative directions may cancel out and be missed. However, the range of fields investigated and listed in Table I is designed to drill down into individual effects similar to those explicitly investigated by IROC. ACDS also has two levels of Pass; Pass (optimal level) and Pass (action level), allowing for identification of results that can be improved, even if the beam is overall acceptable. Optimal level occurs for dosimetry within or equal to ±1.4% and ±3.3% for reference and non-reference dosimetry, respectively.

Throughout this report, any result that is not optimal and would result in a recommendation (being outside IROC’s tolerance or the action level as categorized by the ACDS) will be noted by “R.”

3. RESULTS AND DISCUSSION

3.A. Reference dosimetry

The results for reference dosimetry measurements are shown in Table II, and demonstrate excellent agreement between the two audits, particularly for photon beams. The measurements of FFF photons show a slight discrepancy due to the inclusion of a 0.5% nonuniformity correction included by the ACDS but not included by IROC at the time of this audit. The nonuniformity correction was not included by the facility, which led to an action level result in the ACDS audit. The nonuniformity correction was not included by the facility, which led to an action level result in the ACDS audit. Measurements of reference dosimetry in electron beams between the two groups also showed good agreement, with a maximum discrepancy of 0.8%. The results of the reference modalities confirm the success of the international system of dosimetry: good agreement in measurements from the two groups was seen despite following different dosimetry protocols; IROC uses the AAPM TG-51 protocol while the ACDS uses IAEA TRS-398 and traceability to different primary standards.

3.B. Output factors

The ratio of measured output factors to the TPS calculated output factors at the facility for both audit groups is shown in Table III. Good agreement was seen between IROC and the ACDS for the 20 × 20 cm² and 3 × 3 cm² reference cases.

### Table II. Audit results for the 10 × 10 cm² reference beam outputs, showing the ratio of audit measured output to that determined by the facility.

| Energy | IROC/facility | ACDS/facility | Difference IROC-ACDS |
|--------|---------------|---------------|-----------------------|
| Photons|               |               |                       |
| 6      | 1.011         | 1.010         | 0.1%                  |
| 10FFF  | 1.009         | 1.016²        | −0.7%                 |
| 18     | 1.012         | 1.012         | 0.0%                  |
| Electrons|             |               |                       |
| 6      | 0.991         | 0.998         | −0.7%                 |
| 9      | 0.989         | 0.995         | −0.6%                 |
| 12     | 0.990         | 0.995         | −0.5%                 |
| 15     | 0.988         | 0.993         | −0.5%                 |
| 18     | 1.002         | 0.994         | 0.8%                  |

ACDS, Australian clinical dosimetry service; IROC, imaging and radiation oncology core.
²Nonoptimal result resulting in recommendation.

For the small field (2 × 2 cm), a difference of 0.8% was seen, which is reasonable considering the complexities of small field dosimetry measurements.

The results from both audits after the introduction of deliberate errors in the form of increasing the small field output factors in the 6 MV beam model are shown in Table IV. While the results of both audits did pick up the differences, the adjustments made to the beam model were not large enough to show as deficiencies in either group’s audit, and in the case of the 1 × 1 for ACDS measurements, the plan adjustment improved the agreement due to the direction of the original variation between plan and measurement.

3.C. Percent depth dose

IROC performs a thorough set of point dose measurements at different depths and fields sizes to assess the quality of the facility’s modeling of PDD. All measured PDD values
are normalized to the institution’s value at 10 cm depth (for that field size).

In contrast, the ACDS measures the dose at two depths (8 and 15 cm) for select cases: with and without the presence of heterogeneity and wedges for a 12 × 12 cm field size. For the purposes of comparing with the IROC data, the ACDS-generated PDDs were normalized to a depth of 10 cm. Figure 2(a) shows the ratio of measured to TPS PDD factors for both IROC and ACDS. There is excellent agreement between the two audits assessment of PDD, with good plan modeling of PDD observed in both audits.

The impact of an introduced error in the 6 MV beam model (based on increasing the TPR_{20/10} ratios by 3%) is shown in figure Fig. 2(b). The error is seen in both audits as the measured/calculated ratio deviates substantially from unity.

The outcomes of the PDD audit relative to tolerances when compared to the original/clinical plan and the plan containing the introduced error are shown in Table V. For the original plan, both the IROC and ACDS audits performed with a homogeneous water phantom found all results to be optimal. Both audits flagged the introduced PDD error as being deficient.

For the ACDS audits with lung present, the results with the original clinical plan were mainly optimal, but with nonoptimal results observed in the asymmetric fields 10 × 6 cm² with and without wedge. The individual nonoptimal points were near the water and lung juncture. An interesting result from the ACDS audit is the observed change when the lung slab is present and the PDD error is introduced. When the PDD error was introduced into the model, the lung case (no wedge) measured at 8 cm depth was sensitive to the change, with central axis dose difference increasing by 2%. The measurement at 15 cm depth was insensitive to the introduced PDD error. In contrast, with the homogeneous phantom, the central axis dose difference at 15 cm depth decreases by 2% and the 8 cm depth was insensitive.

The ACDS audit does not correct for the measured daily output. If the ACDS were to correct for the measured daily output of 1.012 cGy/MU for 6X, the results shown in Table V would improve. The results from the plan with introduced errors would then all be in the optimal range.

In comparing the two audit results, strengths and weaknesses in each are seen. A relative strength of the IROC audit is that the range of discrepancy in the PDD values (for the introduced error) identified by IROC was larger due to their more extensive testing of different depths and field sizes. Measurements at shallower and deeper depths identify more problems than those close to the normalization depth. A relative strength of the ACDS audit is the inclusion of the lung case, which showed a systematic behavior with the introduced PDD error.

The IROC additionally measured electron depths of 80% and 50% doses. All measurements agreed to within 1 mm to the institution’s stated depth. The ACDS does not measure electron depth dose data.

### 3.D. Wedge

The IROC and ACDS audits both assess accuracy of the dose calculation in the presence of wedges; IROC calculates wedge factors, and ACDS measures the dose delivered in a wedged field directly without normalization to the open field. In the comparison, IROC measured the 45° and 60° wedges with both a physical wedge and enhanced dynamic wedges (EDW). ACDS measured the EDW for 30° and 60° wedges. The results from the IROC and ACDS wedge measurements in a homogeneous water phantom are shown in Table VI. The
ACDS results are presented as the ratio between measured and TPS calculated wedge factors (for direct comparison with IROC results) and as the ratio of measured and TPS calculated doses. Both audits saw highly consistent results in the ratio of measured vs planned wedge factors. Both the IROC and the ACDS found optimal results for the homogeneous water phantom based on the original (clinical) plan, indicating good modeling of the wedges.

To evaluate the sensitivity of the two audits with respect to identifying wedge issues, the plans with a 30° EDW were replaced with a 25° EDW. IROC did not directly measure the 30° EDW due to time limitations during the comparison. The wedge factors measured by IROC showed minimal variation from the facility plan (0.0%–0.2%), and the ACDS measurements including the 30° EDW also showed minimal variation (0.1%). Therefore, it was assumed the IROC measurement of the 30° EDW would also show minimal variation (0.0%) from the actual plan for the purpose of this sensitivity test. Table VII shows the outcomes form the audits when the plan with the incorrect wedge was introduced. The incorrect wedge was flagged in both audits.

In this case of using a 25° EDW instead of a 30° EDW, the ACDS audit show greater sensitivity to the error than IROC’s measurement on the central axis. Figure 3 provides insight into the reason behind this. It shows the 2D results from the plan with the introduced error. At central axis, the discrepancy is approximately 3%, but at the toe of the wedge, the discrepancy increases to almost 7%. In this case, the 2D information from the wedge is able to highlight discrepancies from the entire field. The ACDS audit does not correct for the measured daily output. If the ACDS were to correct for the measured daily output of 1.012 cGy/MU for 6X, the results shown in Table VII would improve, but the results from the plan with introduced errors would still be out of tolerance.

### 3.E. Off-axis factors

Both audits investigate off-axis factors. As the ACDS audit is array based, every field includes off-axis factors. However, IROC investigates in a much larger field than ACDS, 40 × 40 cm², compared to the maximum 20 × 20 cm² used by the ACDS. In Fig. 4, the off-axis factors measured by each group in maximum field size in the left–right direction are compared. Very similar results were seen with both groups, showing very good agreement with the facility plans, and a very small trend with increasing discrepancy from left to right.

### 3.F. Overall outcome

With the original TPS calculated plans, based on the clinical beam model, almost all results were optimal, and almost all findings were consistent between the two audit
IROC case difference across the two-dimensional (2D) plane in field. Includes both the central axis (CAX) dose variations and the maximum dose of measured to plan wedge factors. ACDS measurements have also been conducted for a 6 MV beam in a homogeneous water phantom. IROC reports the ratio of measured to plan wedge factors. ACDS measurements have also been conducted for a 6 MV beam in a homogeneous water phantom. IROC reports the ratio of measured to plan wedge factors.

| IROC case | ACDS case | ACDS/ facility dose central axis (Max) |
|-----------|-----------|--------------------------------------|
| EDW       | EDW       | EDW                                  |
| 60° EDW   | 60° EDW   | 1.002 (1.012)                        |
| 10 × 10, 10 cm | 10 × 6, 15 cm | 1.002 (1.012) |
| 45° EDW   | 30° EDW   | 1.000 (1.008)                        |
| 10 × 10, 10 cm | 12 × 12,15 cm | 1.001 (1.011) |
| 45° EDW   | 30° EDW   | 1.000 (1.012)                        |
| 15 × 15, 15 cm | 12 × 12, 8 cm | 1.001 (1.015) |

Physical wedge

| IROC case | ACDS case | ACDS/ facility dose central axis (Max) |
|-----------|-----------|--------------------------------------|
| 60° upper | 0.998     |                                       |
| 45° upper | 1.006     |                                       |

*ACDS, Australian clinical dosimetry service; IROC, imaging and radiation oncology core.*

**TABLE VII. Audit outcomes for testing the wedge component of beam model for the 6 MV beam in a homogeneous water phantom with the actual plans and the adjusted plans with incorrect wedge profile included.**

| IROC/facility WF central axis | ACDS/facility dose central axis (max dose variation across 2D plane) |
|-------------------------------|---------------------------------------------------------------|
| Plan                      | Error plan         | Plan                      | Error plan         |
| Case                        |                   | Case                        |                   |
| 30° EDW                     | 1.000^a           | 0.972^R                    | 30° EDW           | 1.008             | 0.967             |
| 10 × 10, 10 cm              |                   | 12 × 12,15 cm              | (1.011)           | (0.939)^R         |
| 30° EDW                     | 1.012             | 0.971^R                    | 12 × 12, 8 cm     | (1.015)           | (0.940)^R         |

*ACDS, Australian clinical dosimetry service; IROC, imaging and radiation oncology core.*

^aNot measured.

^RNonoptimal result resulting in recommendation.

There were differences in the methodologies that resulted in detectable but small differences in results. For example, the 2D array used by the ADCS was more sensitive to the particular error introduced in the wedge data as it also measured the greater discrepancy off axis in the toe of the wedge than the corresponding measurements by IROC. The range of PDD measurements performed by IROC was more sensitive to detecting errors in the PDD than the suite of measurements conducted by the ADCS. There were also some audit aspects that were unique, for example, use of a lung slab phantom by the ADCS or the assessment of depth dependence of electron beams by IROC. Overall, these test differences and differences in sensitivities provide an opportunity for growth for each of IROC and the ADCS.

The two audit approaches also displayed a similar response when errors were introduced into the treatment planning system. They both flagged the incorrect PDD and wedge data, and neither was able to pick up the 2% change to small field output factors.

There were differences in the methodologies that resulted in detectable but small differences in results. For example, the 2D array used by the ADCS was more sensitive to the particular error introduced in the wedge data as it also measured the greater discrepancy off axis in the toe of the wedge than the corresponding measurements by IROC. The range of PDD measurements performed by IROC was more sensitive to detecting errors in the PDD than the suite of measurements conducted by the ADCS. There were also some audit aspects that were unique, for example, use of a lung slab phantom by the ADCS or the assessment of depth dependence of electron beams by IROC. Overall, these test differences and differences in sensitivities provide an opportunity for growth for each of IROC and the ACDS.

The tests performed in this comparison are only a subset of each group’s site dosimetry review visits. IROC also conducts a thorough review of the institution’s QA procedures and documentation; treatment records, assessment of IGRT capability, and MLC calibration. The scope of the ACDS on-site visits are focused on dosimetry measurements, but are not limited to fundamental beam modeling and conformal delivery. The ACDS also measures IMRT, VMAT, and SBRT treatment plans, MLC calibration, and IGRT capability while on-site. Despite the expansion of the audit into advanced modalities, there are continued recommendations generated from the conformal audit component. This fundamental part of dosimetry testing remains relevant to identify flaws in individual implementation of beam models and limitations in commercial algorithms.29 The IROC recommendations similarly continue to show fundamental issues, particularly with small field output factors and wedge factors.9 The broader scope of IROC on-site visit also includes QA program review, with shared aspects with the QUATRO clinical audit approach.30 Although resource intensive, the broader consideration of radiotherapy practice identified...
many areas for improvement with substantial numbers of recommendations relating to deficiencies in the QA program.

The similarities between the findings from the two groups across the core dosimetry assessment are encouraging in the context of seeing similar standards and expectations in radiotherapy dosimetry around the world. As we increasingly move to gathering clinical trial data from international trial participants, it is important that there is a harmonized approach to radiotherapy quality assurance and dosimetry audit.

ACKNOWLEDGMENTS

The IROC Houston QA Center’s contribution was supported by the Public Health Services Grant No. CA180803 and CA214526 awarded by the National Cancer Institute, United States Department of Health and Human Services.

REFERENCES

1. Kry S, Alvarez P, Molineu A, Amador C, Galvin J, Followill DS. Algorithms used in heterogeneous dose calculations show systematic differences as measured with the Radiological Physics Center’s anthropomorphic thorax phantom used for RTOG credentialing. *Int J Radiat Oncol Biol Phys*. 2012;85:95–100.

2. Dunn L, Lehmann J, Lye J, et al. National dosimetric audit network finds discrepancies in AAA lung inhomogeneity corrections. *Phys Med*. 2015;31:435–441.

3. Clark C, Hurkmans C, Kry S. The role of dosimetry audit in lung SBRT multi-centre clinical trials. *Phys Med*. 2017;44:171–176.

4. Taylor PA, Kry SF, Followill DS. Pencil beam algorithms are unsuitable for proton dose calculations in lung. *Int J Radiat Oncol Biol Phys*. 2017;99:750–756.

5. Followill D, Kry S, Qin L, et al. The Radiological Physics Center’s standard dataset for small field size output factors. *J Appl Clin Med Phys*. 2012;13:282–289.

6. Lechner W, Wesolowska P, Azangwe G, et al. A multinational audit of small field output factors calculated by treatment planning systems used in radiotherapy. *Phys Imag Radiat Oncol*. 2018;5:58–63.

7. Kerns JR, Followill DS, Lowenstein J, et al. Agreement between institutional measurements and treatment planning system calculations for basic dosimetric parameters as measured by the imaging and radiation oncology core-Houston. *Int J Radiat Oncol Biol Phys*. 2016;95:1527–1534.

8. Kry S, Peterson B, Howell R, et al. Remote beam output audits: a global assessment of results out of tolerance. *Phys Imag Radiat Oncol*. 2018;7:39–44.

9. Kry SF, Dromgoole L, Alvarez P, et al. Radiation therapy deficiencies identified during on-site dosimetry visits by the Imaging and Radiation Oncology Core Houston Quality Assurance center. *Int J Radiat Oncol Biol Phys*. 2017;99:1094–1100.

10. Kron T, Haworth A, Williams I. Dosimetry for audit and clinical trials: challenges and requirements. *J Phys Conf Ser*. 2013;444:012014.

11. Kron T, Hamilton C, Roff M, Denham J. Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom. *Int J Radiat Oncol Biol Phys*. 2002;52:566–579.

12. Izewska J, Svensson H, Ibbott G. Worldwide quality assurance networks for radiotherapy dosimetry. International Atomic Energy Agency. Standards and codes of practice in medical radiation dosimetry. 2002:2:139–155.

13. Lye J, Kenny J, Lehmann J, et al. A 2D ion chamber array audit of wedged and asymmetric fields in an inhomogeneous lung phantom. *Med Phys*. 2014;41:101712.

14. Melidis C, Bosch WR, Izewska J, et al. Radiation therapy quality assurance in clinical trials – global harmonization group. *Radiother Oncol*. 2014;111:327–329.
15. Kruse JJ. On the insensitivity of single field planar dosimetry to IMRT inaccuracies. *Med Phys*. 2010;37:2516–2524.

16. Nelms BE, Zhen H, Tome WA. Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors. *Med Phys*. 2011;38:1037–1044.

17. McKenzie E, Balter P, Stingo F, Jones J, Followill D, Kry S. Reproducibility in patient-specific IMRT QA. *J Appl Clin Med Phys*. 2014;15:241–251.

18. Kry SF, Molineu A, Kerrs JR, et al. Institutional patient-specific IMRT QA does not predict unacceptable plan delivery. *Int J Radiat Oncol Biol Phys*. 2014;90:1195–1201.

19. Defoor DL, Stathakis S, Roring JE, et al. Investigation of error detection capabilities of phantom, EPID, and MLC log file based IMRT QA methods. *J Appl Clin Med Phys*. 2017;18:172–179.

20. Almond PR, Biggs PJ, Coursey BM, et al. AAPM’s TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. *Med Phys*. 1999;26:1847–1870.

21. Andreo P, Burns DT, Hohlfield K, Huq MS, Kanai T, Laitano F, Smith VG, Vynckier S. 2000 Absorbed dose determination in external beam radiotherapy: an international Code of Practice for dosimetry based on standards of absorbed dose to water IAEA Technical Report Series No 398 (Vienna: International Atomic Energy Agency) and the updated version 12 issued in 2006.

22. Ezzell G, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM TG 119. *Med Phys*. 2009;36:5359–5373.

23. Van Esch A, Bohsung J, Sorvani P, et al. Acceptance tests and quality control (QC) procedures for the clinical implementation of intensity modulated radiotherapy (IMRT) using inverse planning and the sliding window technique: experience from five radiotherapy departments. *Radiother Oncol*. 2002;65:53–70.

24. McEwen M, DeWerd L, Ibbott G, et al. Addendum to the AAPM’s TG-51 protocol for clinical reference dosimetry of high-energy photon beams. *Med Phys*. 2014;41:041501.

25. Monaco Technical Reference LRMMON0003.

26. Lye JE, Butler DJ, Oliver CP, et al. Comparison between the TRS-398 code of practice and the TG-51 dosimetry protocol for flattening filter free beams. *Phys Med Biol*. 2016;61:N362–N372.

27. The BIPM key comparison database: https://kcdb.bipm.org/.

28. Huq S, Andreo P, Song H. Comparison of the IAEA TRS-398 and AAPM TG-51 absorbed dose to water protocols in the dosimetry of high-energy photon and electron beams. *PMB*. 2001;46:2985–3006.

29. Lehmann L, Alves A, Dunn L, et al. Dosimetric end-to-end tests in a national audit of 3D conformal radiotherapy. *Phys Imaging Radiat Oncol*. 2018;6:5–11.

30. Izewska J, Coffey M, Scalliet P, et al. Improving the quality of radiation oncology: 10 years’ experience of QUATRO audits in the IAEA Europe Region. *Radiother Oncol*. 2018;126:183–119.
Author/s:
Lye, J; Kry, S; Shaw, M; Gibbons, F; Keehan, S; Lehmann, J; Kron, T; Followill, D; Williams, I

Title:
A comparison of IROC and ACDS on-site audits of reference and non-reference dosimetry

Date:
2019-12

Citation:
Lye, J., Kry, S., Shaw, M., Gibbons, F., Keehan, S., Lehmann, J., Kron, T., Followill, D. & Williams, I. (2019). A comparison of IROC and ACDS on-site audits of reference and non-reference dosimetry. MEDICAL PHYSICS, 46 (12), pp.5878-5887. https://doi.org/10.1002/mp.13800.

Persistent Link:
http://hdl.handle.net/11343/246531

File Description:
published version

License:
CC BY